On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Snoring can be a sign of hypothyroidism, as low thyroid hormone levels may weaken respiratory muscles, contributing to airway ...

“People who experience SRED are at an increased risk of fatigue, depression and weight gain,” Johnston said. They’re also at ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Gal-475 is under clinical development by Neurim Pharmaceuticals and currently in Phase I for Sleep Apnea. According to GlobalData, Phase I drugs for Sleep Apnea have a 96% phase t ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Pitolisant hydrochloride is under clinical development by Bioprojet SCR and currently in Phase II for Autism Spectrum Disorder (ASD).

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

In some cases, snoring can indicate various underlying health conditions, such as sleep apnea, obesity, or chronic nasal ...

“Weighted blankets provide deep pressure stimulation, a form of tactile stimulation that involves gentle, even pressure ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

The U.S. Food and Drug Administration (FDA) has approved Zepbound, a prescription weight-loss medication, as the first drug ...